LMT’s comprehensive sales and support network to meet significant demand
for the MolecuLight I:X® in the wound care community
TORONTO and QUEENSLAND, Australia, June 22, 2021 / PRNewswire / – MolecuLight Inc., the leader in point-of-care fluorescence imaging for the detection of wounds containing high bacterial loads, announces it has signed Surgical LMT as a new distributor in Australia and New Zealand. LMT, one of the leading providers of products and services in the medical market, will bring its full business capabilities to help meet the significant demand for MolecuLight I:X to the wound care community by Australia and New Zealand.
“We are delighted to be working with LMT Surgical to provide the support and training necessary for the growing demand for our MolecuLight I:X point of service device in Australia and New Zealand“Says Anil Amlani, CEO of MolecuLight.” We believe LMT, with its impressive team and strong relationships with leading clinicians and medical institutions, is the ideal partner for MolecuLight. “
“We are very happy to start collaborating with MolecuLight and to promote the I:X system in Australia and New Zealand. The MolecuLight I:X device will seamlessly complement our extensive wound care portfolio, ”says Daniel Jones, general manager of sales and marketing of LMT Surgical.
LMT joins MolecuLight Global distribution network which distributes and supports its products internationally. MolecuLight has a direct sales and clinical applications support team in United States and Canada.
To book a demonstration of the MolecuLight I: X technology in Australia or New Zealand, please contact [email protected]
About LMT Surgical
Surgical LMT is a leading provider of products and services to the orthopedics, spine, neurology, robotics, plastics, biologics, sports medicine and wound management communities. Australia and New Zealand For more than 20 years. LMT offers a product portfolio that covers most of the pathologies and philosophies required by these physicians, proud to partner with healthcare professionals throughout their careers to achieve the best outcomes for clinicians and their patients.
About MolecuLight Inc.
MolecuLight Inc., a private medical imaging company that has developed and commercialized its proprietary fluorescence imaging platform technology in several clinical markets. The first device marketed by MolecuLight, the MolecuLight I:X The fluorescence imaging system and its accessories provide a portable point-of-care imaging device for the global wound care market for the detection of wounds containing elevated bacterial burden (when used with clinical signs and symptoms) and for digital wound measurement. The company is also commercializing its unique fluorescence imaging platform technology for other markets with unmet and globally relevant needs, including food safety, consumer cosmetics and other key industrial markets. .
View original content to download multimedia:http://www.prnewswire.com/news-releases/moleculight-signs-lmt-surgical-as-new-distributor-for-australia-and-new-zealand-301316925.html